- Home
- APVO vs AQMS Comparison
APVO vs AQMS Comparison
Compare APVO & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- AQMS
- Stock Information
- Founded
- APVO 2016
- AQMS 2014
- Country
- APVO United States
- AQMS United States
- Employees
- APVO N/A
- AQMS N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- AQMS Metal Fabrications
- Sector
- APVO Health Care
- AQMS Industrials
- Exchange
- APVO Nasdaq
- AQMS Nasdaq
- Market Cap
- APVO 21.7M
- AQMS 24.2M
- IPO Year
- APVO N/A
- AQMS 2015
- Fundamental
- Price
- APVO $1.46
- AQMS $7.30
- Analyst Decision
- APVO
- AQMS Buy
- Analyst Count
- APVO 0
- AQMS 1
- Target Price
- APVO N/A
- AQMS $12.00
- AVG Volume (30 Days)
- APVO 4.5M
- AQMS 3.9M
- Earning Date
- APVO 11-10-2025
- AQMS 11-13-2025
- Dividend Yield
- APVO N/A
- AQMS N/A
- EPS Growth
- APVO N/A
- AQMS N/A
- EPS
- APVO N/A
- AQMS N/A
- Revenue
- APVO N/A
- AQMS N/A
- Revenue This Year
- APVO N/A
- AQMS N/A
- Revenue Next Year
- APVO N/A
- AQMS $550.00
- P/E Ratio
- APVO N/A
- AQMS N/A
- Revenue Growth
- APVO N/A
- AQMS N/A
- 52 Week Low
- APVO $1.32
- AQMS $3.37
- 52 Week High
- APVO $298.00
- AQMS $39.40
- Technical
- Relative Strength Index (RSI)
- APVO 42.13
- AQMS 46.72
- Support Level
- APVO $1.48
- AQMS $9.00
- Resistance Level
- APVO $1.57
- AQMS $10.48
- Average True Range (ATR)
- APVO 0.09
- AQMS 4.65
- MACD
- APVO 0.00
- AQMS -0.81
- Stochastic Oscillator
- APVO 0.00
- AQMS 6.01
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.